Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal malignancy: preliminary results of a multi-disciplinary teamwork model in Asia

References

• Spratt JS, Adcock RA, Muskovin M, et al. (1980). Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40:256–60.
   PubMed Web of Science ®Google Scholar
• Yan TD, Stuart OA, Yoo D, Sugarbaker PH. (2006). Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy. J Transl Med 4:17.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin S, Boot H, et al. (2008). 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 15:2426–32.
   PubMed Web of Science ®Google Scholar
• Mirnezami R, Mehta AM, Chandrakumaran K, et al. (2014). Cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy improves survival in patients with colorectal peritoneal metastases compared with systemic chemotherapy alone. Br J Cancer 111:1500.
   PubMed Web of Science ®Google Scholar
• Chua TC, Moran BJ, Sugarbaker PH, et al. (2012). Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol 30:2449–56.
   PubMed Web of Science ®Google Scholar
• D'Hondt V, Goffin F, Roca L, et al. (2016). Interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in first-line treatment for advanced ovarian carcinoma: a feasibility study. Int J Gynecol Cancer 26:912–17.
   PubMed Web of Science ®Google Scholar
• Kusamura S, Baratti D, Virzi S, et al. (2013). Learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies: analysis of two centres. J Surg Oncol 107:312–19.
   PubMed Web of Science ®Google Scholar
• Smeenk RM, Verwaal VJ, Zoetmulder FA. (2007). Learning curve of combined modality treatment in peritoneal surface disease. Br J Surg 94:1408–14.
   PubMed Web of Science ®Google Scholar
• Tan G, Chia C, Kumar M, et al. (2017). 201 consecutive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in a single Asian tertiary centre. Int J Hyperthermia 33:288–94.
   PubMed Web of Science ®Google Scholar
• Kuijpers AM, Hauptmann M, Aalbers AG, et al. (2016). Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol 42:244–50.
   PubMed Web of Science ®Google Scholar
• Chang KH, Kazanowski M, Staunton O, et al. (2017). Mentored experience of establishing a national peritoneal malignancy programme – experience of first 50 operative cases. Eur J Surg Oncol 43:395–400.
   PubMed Web of Science ®Google Scholar
• Kang LY, Mok KT, Liu SI, et al. (2013). Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion. J Chin Med Assoc 76:425–31.
   PubMed Web of Science ®Google Scholar
• Lin EK, Hsieh MC, Chen CH, et al. (2016). Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with peritoneal metastasis. Medicine (Baltimore) 95:e5522.
   PubMed Web of Science ®Google Scholar
• Lungoci C, Mironiuc AI, Muntean V, et al. (2016). Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol 8:67–82.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. (2016). Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: progress toward a new standard of care. Cancer Treat Rev 48:42–9.
   PubMed Web of Science ®Google Scholar
• Mogal HD, Levine EA, Fino NF, et al. (2016). Routine admission to intensive care unit after cytoreductive surgery and heated intraperitoneal chemotherapy: not always a requirement. Ann Surg Oncol 23:1486–95.
   PubMedGoogle Scholar
• Sugarbaker PH. (2007). Peritonectomy procedures. Cancer Treat Res 134:247–64.
   PubMedGoogle Scholar
• Turaga K, Levine E, Barone R, et al. (2014). Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 21:1501–5.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, et al. (2015). Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 22:1570–5.
   PubMed Web of Science ®Google Scholar
• Delotte J, Desantis M, Frigenza M, et al. (2014). Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. Eur J Obstet Gynecol Reprod Biol 172:111–14.
   PubMed Web of Science ®Google Scholar
• Roviello F, Caruso S, Neri A, Marrelli D. (2013). Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol 39:1309–16.
   PubMed Web of Science ®Google Scholar
• Pascual-Ramirez J, Garcia SS, Gonzalez Ruiz de la Herran F, et al. (2014). Security and efficiency of a closed-system, turbulent-flow circuit for hyperthermic intraperitoneal chemotherapy after cytoreductive ovarian surgery: perioperative outputs. Arch Gynecol Obstet 290:121–9.
   PubMed Web of Science ®Google Scholar
• Sommariva A, Zagonel V, Rossi CR. (2012). The role of laparoscopy in peritoneal surface malignancies selected for hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 19:3737–44.
   PubMed Web of Science ®Google Scholar
• Ihemelandu CU, McQuellon R, Shen P, et al. (2013). Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS + HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol 20:3519–26.
   PubMed Web of Science ®Google Scholar
• Webb CA, Weyker PD, Moitra VK, Raker RK. (2013). An overview of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for the anesthesiologist. Anesth Analg 116:924–31.
   PubMed Web of Science ®Google Scholar
• Valle SJ, Alzahrani NA, Alzahrani SE, et al. (2015). Laparoscopic hyperthermic intraperitoneal chemotherapy (HIPEC) for refractory malignant ascites in patients unsuitable for cytoreductive surgery. Int J Surg 23:176–80.
   PubMed Web of Science ®Google Scholar
• Randle RW, Swett KR, Swords DS, et al. (2014). Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21:1474–9.
   PubMed Web of Science ®Google Scholar
• Herzer KR, Rodriguez-Paz JM, Doyle PA, et al. (2009). A practical framework for patient care teams to prospectively identify and mitigate clinical hazards. Jt Comm J Qual Patient Saf 35:72–81.
   PubMedGoogle Scholar
• Rodriguez-Paz JM, Mark LJ, Herzer KR, et al. (2009). A novel process for introducing a new intraoperative program: a multidisciplinary paradigm for mitigating hazards and improving patient safety. Anesth Analg 108:202–10.
   PubMed Web of Science ®Google Scholar
• Moran BJ. (2006). Decision-making and technical factors account for the learning curve in complex surgery. J Public Health (Oxf) 28:375–8.
   PubMed Web of Science ®Google Scholar